Skip to main content

Table 1 Patient demographics and characteristics (safety population) and lung function at baseline (intent-to-treat [ITT] population)

From: Efficacy and safety of fluticasone furoate 100 μg and 200 μg once daily in the treatment of moderate-severe asthma in adults and adolescents: a 24-week randomised study

  FF 100 μg FF 200 μg Total
Patient demographics (safety population)
N 119 119 238
Age, years 46.6 (15.4) 45.1 (15.8) 45.9 (15.6)
(range) (12–76) (12–70) (12–76)
Female sex, n (%) 81 (68) 79 (66) 160 (67)
White race, n (%) 101 (85) 100 (84) 201 (84)
Patient characteristics (safety population)
Duration of asthma, years 20.1 (15.9) 21.5 (15.0) 20.8 (15.4)
≥ 1 exacerbation in prior 12 months, n (%) 73 (61) 67 (56) 140 (59)
Lung function parameters (ITT population)
N 108* 111 219*
Percent reversibility FEV1 at screening,% 30.6 (16.1) 33.9 (20.6) 32.3 (18.5)
Pre-dose FEV1 at baseline, L 2.04 (0.67) 2.08 (0.65) 2.06 (0.66)
Percent predicted FEV1 at baseline,% 68.4 (14.0) 67.8 (13.3) 68.1 (13.6)
  1. All data are mean (SD) unless otherwise stated.
  2. *Baseline lung function data available for 107 patients in the FF 100 μg group (218 in total).
  3. FF = fluticasone furoate; NA = not applicable; SD = standard deviation.